BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Biogen
• Treatments: 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine; Midazolam; Rosiglitazone; Warfarin

Criteria

Inclusion Criteria:

• Healthy male or female subjects

• Between the ages of 18 and 45, inclusive.

• Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive

Exclusion Criteria:

• Clinically significant abnormalities (as determined by the Investigator)

• Other unspecified reason that would make the subject unsuitable for enrollment (as determined by the Investigator)